Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
An Adult Case of Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Multiphasic Acute Disseminated Encephalomyelitis at 33-year Intervals.
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
Drug record: Amiloride
Neuroprotective effects of riluzole in neurotrauma models: a review.
Guillain-Barré syndrome in Colombia: where do we stand now?
The role of growth factors as a therapeutic approach to demyelinating disease.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
Ximino
A biopsychosocial model of resilience for multiple sclerosis.
[Immunodepressive therapy in neurology].
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
The effect of an AFO-shaped elastic band on drop-foot gait in patients with central neurological lesions.
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS)
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Multiple sclerosis: An old drug plays a new trick.
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
The safety of exercise training in multiple sclerosis: A systematic review.
Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells.
PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.
Pages
« first
‹ previous
…
168
169
170
171
172
173
174
175
176
…
next ›
last »